TY - JOUR
T1 - Leptin receptor deficiency
T2 - a systematic literature review and prevalence estimation based on population genetics
AU - Kleinendorst, Lotte
AU - Abawi, Ozair
AU - van der Kamp, Hetty J
AU - Alders, Mariëlle
AU - Meijers-Heijboer, Hanne E J
AU - van Rossum, Elisabeth F C
AU - van den Akker, Erica
AU - van Haelst, Mieke M
N1 - Funding Information:
O A was supported by the Elisabeth Foundation, a non-profit foundation supporting academic obesity research. The authors thank the (corresponding) authors of papers describing patients with LepR deficiency who provided additional patient details: Prof. I Mazen, Prof. W K Chung, Prof. T Hansen, Prof. M Arslan, Prof. P Froguel, Prof. R Jockers, Dr A Bi?gin, Dr R K Niazi, Dr J Dam, Dr N Mirza, Dr R Rodr?guez L?pez, and R Melero Valverde. The authors thank U ?zayd?n, computer scientist, and K Mauff, statistician, for their help with the prevalence calculation and E Krabbendam, biomedical information specialist, for her help with the systematic literature search.
Funding Information:
O A was supported by the Elisabeth Foundation, a non-profit foundation supporting academic obesity research.
Publisher Copyright:
© 2019 European Society of Endocrinology Printed in Great Britain
PY - 2020/1
Y1 - 2020/1
N2 - Objective: Leptin receptor (LepR) deficiency is an autosomal-recessive endocrine disorder causing early-onset severe obesity, hyperphagia and pituitary hormone deficiencies. As effective pharmacological treatment has recently been developed, diagnosing LepR deficiency is urgent. However, recognition is challenging and prevalence is unknown. We aim to elucidate the clinical spectrum and to estimate the prevalence of LepR deficiency in Europe. Design: Comprehensive epidemiologic analysis and systematic literature review. Methods: We curated a list of LEPR variants described in patients and elaborately evaluated their phenotypes. Subsequently, we extracted allele frequencies from the Genome Aggregation Database (gnomAD), consisting of sequencing data of 77 165 European individuals. We then calculated the number of individuals with biallelic disease-causing LEPR variants. Results: Worldwide, 86 patients with LepR deficiency are published. We add two new patients, bringing the total of published patients to 88, of which 21 are European. All patients had early-onset obesity; 96% had hyperphagia; 34% had one or more pituitary hormone deficiencies. Our calculation results in 998 predicted patients in Europe, corresponding to a prevalence of 1.34 per 1 million people (95% CI: 0.95-1.72). Conclusions: This study shows that LepR deficiency is more prevalent in Europe (n = 998 predicted patients) than currently known (n = 21 patients), suggesting that LepR deficiency is underdiagnosed. An important cause for this could be lack of access to genetic testing. Another possible explanation is insufficient recognition, as only one-third of patients has pituitary hormone deficiencies. With novel highly effective treatment emerging, diagnosing LepR deficiency is more important than ever.
AB - Objective: Leptin receptor (LepR) deficiency is an autosomal-recessive endocrine disorder causing early-onset severe obesity, hyperphagia and pituitary hormone deficiencies. As effective pharmacological treatment has recently been developed, diagnosing LepR deficiency is urgent. However, recognition is challenging and prevalence is unknown. We aim to elucidate the clinical spectrum and to estimate the prevalence of LepR deficiency in Europe. Design: Comprehensive epidemiologic analysis and systematic literature review. Methods: We curated a list of LEPR variants described in patients and elaborately evaluated their phenotypes. Subsequently, we extracted allele frequencies from the Genome Aggregation Database (gnomAD), consisting of sequencing data of 77 165 European individuals. We then calculated the number of individuals with biallelic disease-causing LEPR variants. Results: Worldwide, 86 patients with LepR deficiency are published. We add two new patients, bringing the total of published patients to 88, of which 21 are European. All patients had early-onset obesity; 96% had hyperphagia; 34% had one or more pituitary hormone deficiencies. Our calculation results in 998 predicted patients in Europe, corresponding to a prevalence of 1.34 per 1 million people (95% CI: 0.95-1.72). Conclusions: This study shows that LepR deficiency is more prevalent in Europe (n = 998 predicted patients) than currently known (n = 21 patients), suggesting that LepR deficiency is underdiagnosed. An important cause for this could be lack of access to genetic testing. Another possible explanation is insufficient recognition, as only one-third of patients has pituitary hormone deficiencies. With novel highly effective treatment emerging, diagnosing LepR deficiency is more important than ever.
UR - http://www.scopus.com/inward/record.url?scp=85078087627&partnerID=8YFLogxK
U2 - 10.1530/EJE-19-0678
DO - 10.1530/EJE-19-0678
M3 - Article
C2 - 31658438
SN - 0804-4643
VL - 182
SP - 47
EP - 56
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 1
ER -